Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Patent
1995-02-24
1997-04-22
Rollins, John W.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
514906, 514923, A61K 3578
Patent
active
056227043
DESCRIPTION:
BRIEF SUMMARY
The invention relates to a novel use of a combination product with active substances constituted by Rhizoma zingiberis and Ginkgo bilobae for the treatment of anxiety states.
Fear and anxiety states are typical human phenomena which, as a result of their secondary phenomena in the form of behavioural changes and disturbances in the vegetative nervous system, lead to a marked decrease in the quality of life. Triggered by overwork, compulsive situations, failures in professional and private life and other stress effects typical psychosomatic symptoms are manifested. These include escape and avoidance reactions, as well as disturbances in the vegetative field, such as intestinal and stomach complaints or the proverbial "lump in the throat".
When the triggering or provoking factors are accumulated there can be a psychovegetative exhaustion-syndrome, which is characterized by a decrease in efficiency with psychic and vegetative disturbances such as headaches, stomach pains, lack of concentration, irritability and sleep disturbances.
The biochemical, pharmacological and neurophysiological mechanisms forming the basis for this syndrome have not been completely clarified and are probably also not of a unitary nature. It can fundamentally be assumed that the homoeostatis of the neurotransmitter systems noradrenaline, dopamine and 5-hydroxytryptamine is disturbed. It is also assumed that apart from the action via the monoaminergic synopses the endogenic .gamma.-aminobutyric acid and/or transmitter systems interacting therewith participate in provoking the symptoms. Information exists showing that in such situations the blood-brain barrier becomes more permeable for low molecular weight peptides, so that the latter can have effects on the central nervous plane.
For the therapy of psychoreactive disturbances at present only medicaments are used which belong to the group of psychopharmaceuticals. The preferred group consists of tranquillizers, also known as anxiolytics, with the benzodiazepines and their derivatives most frequently used in this field throughout the world. These active substances act in the metabolism of the endogenic .gamma.-aminobutyric acid in that they react with specific bonding points belonging to a complex comprising the GABA receptor, benzodiazapine receptor and an ion channel for chloride ions. These receptors are present throughout the central nervous system.
Depending on the extent to which these symptoms apply use is also made of neuroleptics, which act in regularizing manner in the monoamine metabolism, such as phenothiazines. If there is a deficiency of catecholamines and serotonin (5-hydroxytryptamine) therapeutic results can be achieved with derivatives of phenothiazine, i.e. tricyclic antidepressants.
In the field of phytopharmaceuticals antidepressive actions are only attributed to St. John's wort. In the foreground there is an improvement on the mood, but opinions concerning neurovegetative actions are not uniform and in part in dispute.
It is generally considered disadvantageous in the hitherto used medicamentus treatment that the tranquillizers, as well as neuroleptics and antidepressants, apart from their desired main action, i.e. anxiolysis, lead to a number of undesired side effects. These in particular include sedation, which leads to tiredness and an increased need for sleep. The muscle-relaxing action can have an unfavourable effect in high dosages. As a result of the usually long-lasting therapy, the hepatic metabolism is significantly stressed.
In addition, tranquillizers closely interact with other centrally acting pharmaceuticals, such as hypnotics, as well as analgesics, stimulants and alcohol. Generally the effects of these substances are reinforced and in part there are even effects, which are not or only slightly noticed after administering the individual substances.
This situation has led to a worldwide search for further substances and/or derivatives of known active substances in order to minimize these disadvantages. The problem of the present invention is to meet t
REFERENCES:
patent: 4639466 (1987-01-01), Huarge et al.
Notice of Opposition.
Santa V, Dr. Carlos E. Pietra et al., Eficacia del extracto estandarizado de Ginkgo-Biloba EGB 761* en el tratamiento de la insuficiencia vascular cerebral, Investigation Medica International, vol. 17, No. 3, (1990), pp. 130-141.
Warburton, D.M., Psycnh-pharmacologie clinique de i'extrait de Ginkgo biloba, La Presse Medicale, Bd. 15, Nr. 31, (1986), pp. 1595-1604.
Eckmann, Von F., Himleistungsstorungen-Behandlong mit Ginkgo-biloba-Extrakt, Fortschritte der Medizin, Bd. 108, Nr. 29, (1990), pp. 557-560.
Schenker, H., Akt. Gerontol, 13, (1983), pp. 104-107.
Vorberg, G. et al., Wirksamkeit eines neunen Ginkgo-biloba-Extraktes bei 100 Patienten mit zerebraler Insuffzienz, Herz + Gerasse, Sonderdruck aus Heft, (Jul. 1989), pp. 3-9.
Eckmann, Von. F. et al., Kontrollierte Doppelblind-Studie zum Wirksamkeitsnachweis von Tebonin forte bei Patienten mit zerebrovaskularer Insuffizienz, Fortschritte der Medizin, Bd. 100, Nr. 133, (1991), pp. 1474-1478.
Schmidt, U et al., Einfluss eiens Ginkgo-Spezialextraktes auf die Befindlichkeit bei zerebraler Insuffizienz, Munchener Medizinische Wochenschrift, Nr. 133, (1991), pp. 15-18.
Hagers Handbuch der Pharmazeutischen Praxis, Bd. 6, (1979), p. 574.
Yamahara, Johji et al., Cholagogic Effect of Ginger and Its Active Constituents, Journal of Ethnopharmacology, Nr. 13, (1985), pp. 217-225.
Grontved, Aksel et al., Ginger Root Against Seasickness, Acta Otolaryngol (Stockh), Nr. 105, (1988), pp. 45-49.
R. Saller et al., "Anwendung von Ingwerpraparaten", Intemistische Praxis, Nr. 32, (1992), pp. 386-387.
Fischer-Rasmussen, Wiggo et al., Ginger treatment of hypermesis gravidarum, European Journal of Obstetrics & Gynecology and Reproductive Biology, Nr. 38, (1990), pp. 19-24.
Mowrey, Daniel B. et al., Motion Sickness, Ginger, and Psychophysics, The Lancet, Marz 1982, pp. 655-657.
Yamahara, Johji et al., Gastrointestinal Motility Enhancing Effect of Ginger and Its Active Constitutents, Chem. Phar. Bulletin, Nr. 38(2), (1990), pp. 430-431.
Chem Abst. 119(11):109013h, 1993.
Hacker Rudiger
Mattern Claudia
Arrowdean Limited
Rollins John W.
LandOfFree
Anxiolytic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anxiolytic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anxiolytic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-339810